Biomarin Pharmaceutical (BMRN) Convertible Debt (2009 - 2025)

Biomarin Pharmaceutical has disclosed Convertible Debt across 17 years of filings, most recently posting $597.2 million for Q4 2025.

• Quarterly Convertible Debt changed 0.34% year-over-year to $597.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $597.2 million (changed 0.34% YoY) and the FY2025 annual result came in at $597.2 million, changed 0.34% from the prior year.
• Convertible Debt was little changed at $597.2 million in Q4 2025, from $596.7 million in the prior quarter.
• Over five years, Convertible Debt peaked at $1.1 billion in Q2 2024 and troughed at $592.6 million in Q3 2023.
• A 5-year average of $887.2 million and a median of $1.1 billion in 2021 frame the typical range for Convertible Debt.
• Annual changes were most pronounced in 2021 — Convertible Debt grew 26.21% — and 2025, when it sank 45.25%.
• Tracing BMRN's Convertible Debt over 5 years: stood at $1.1 billion in 2021, then gained by 0.37% to $1.1 billion in 2022, then slumped by 45.24% to $593.1 million in 2023, then rose by 0.34% to $595.1 million in 2024, then climbed by 0.34% to $597.2 million in 2025.
• Business Quant data shows BMRN's Convertible Debt at $597.2 million in Q4 2025, $596.7 million in Q3 2025, and $596.2 million in Q2 2025.